Beauty Health (NASDAQ:SKIN) Issues Earnings Results

Beauty Health (NASDAQ:SKIN) issued its quarterly earnings data on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01), Zacks reports. Beauty Health had a negative return on equity of 32.82% and a negative net margin of 6.13%.The firm had revenue of $70.66 million for the quarter, compared to analysts’ expectations of $68.33 million. Beauty Health updated its FY 2025 guidance to EPS.

Beauty Health Trading Up 8.1%

NASDAQ:SKIN traded up $0.11 during mid-day trading on Friday, hitting $1.40. 4,340,465 shares of the stock traded hands, compared to its average volume of 910,746. The company has a quick ratio of 4.15, a current ratio of 5.15 and a debt-to-equity ratio of 4.91. Beauty Health has a 52 week low of $0.78 and a 52 week high of $2.69. The stock has a market capitalization of $176.91 million, a price-to-earnings ratio of -4.98 and a beta of 1.19. The firm’s 50 day moving average is $1.82 and its two-hundred day moving average is $1.74.

Analyst Upgrades and Downgrades

SKIN has been the topic of a number of recent research reports. Wall Street Zen raised shares of Beauty Health from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Zacks Research upgraded shares of Beauty Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 21st. Cowen reaffirmed a “hold” rating on shares of Beauty Health in a report on Monday, September 22nd. TD Cowen lifted their price target on Beauty Health from $2.00 to $2.50 and gave the stock a “hold” rating in a research report on Monday, September 22nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Beauty Health in a research report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $2.81.

Institutional Investors Weigh In On Beauty Health

Hedge funds and other institutional investors have recently modified their holdings of the business. Invesco Ltd. grew its position in Beauty Health by 6.6% in the 2nd quarter. Invesco Ltd. now owns 98,427 shares of the company’s stock valued at $188,000 after acquiring an additional 6,059 shares during the last quarter. Rhumbline Advisers lifted its holdings in Beauty Health by 5.7% during the 3rd quarter. Rhumbline Advisers now owns 150,124 shares of the company’s stock valued at $299,000 after buying an additional 8,142 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Beauty Health by 33.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 41,488 shares of the company’s stock worth $79,000 after acquiring an additional 10,410 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Beauty Health by 40.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,570 shares of the company’s stock valued at $120,000 after acquiring an additional 18,128 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Beauty Health by 54.1% in the second quarter. JPMorgan Chase & Co. now owns 54,226 shares of the company’s stock valued at $104,000 after purchasing an additional 19,032 shares during the period. 93.26% of the stock is currently owned by hedge funds and other institutional investors.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.